<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Growth failure and pubertal delay in children with inflammatory bowel disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Growth failure and pubertal delay in children with inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Growth failure and pubertal delay in children with inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan E Teitelbaum, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Growth failure is a common extraintestinal manifestation of inflammatory bowel disease (IBD) in children, particularly among those with Crohn disease [<a href="#rid1">1</a>]. The causes of growth failure are complex and include the inflammatory process itself, undernutrition, pubertal delay, and, in some cases, effects of glucocorticoids. Pubertal delay is also associated with undernutrition and inflammation and has secondary effects on growth.</p><p>The pathogenesis, evaluation, and treatment of growth failure or poor weight gain in children and adolescents with IBD will be reviewed here. The assessment and management of micronutrient deficiencies in these patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H3606910149"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth failure</strong> – A variety of anthropometric measures are used to monitor growth in children with IBD. A clinically practical definition of acute growth failure is height velocity &lt;4 cm/year (or &lt;10<sup>th</sup> percentile for age on standard height velocity charts). Chronic growth failure is reflected by decreasing height percentiles over time and/or predicted height substantially lower than genetic potential. Specific parameters to define growth failure are outlined in the Paris Classification for pediatric IBD; one such parameter is difference between observed height Z-score and pre-illness height Z-score &gt;1.0 [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pubertal delay</strong> – Delayed puberty is defined as pubertal onset &gt;2 to 3 standard deviations above the mean age for the relevant population. In the United States, this corresponds to an upper limit of approximately 12 to 13 years for females and approximately 13 to 14 years for males. Stalled puberty refers to abnormally slow pubertal progression after pubertal onset, eg, no significant pubertal progression for two or more years.</p><p></p><p>These thresholds are not absolute, and children may warrant additional monitoring and attention to nutrition and IBD management before the above thresholds are reached. (See <a class="local">'Routine monitoring of growth and puberty'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS OF GROWTH FAILURE</span><span class="headingEndMark"> — </span>A combination of factors contribute to the pathogenesis of growth failure in children with IBD. Different clinical variables are associated with growth in male versus female children with Crohn disease. For example, poorer growth was seen in females with arthralgia at symptom onset and in males with mouth sores [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammation</strong> – Inflammation appears to be an important mediator of growth failure in children with IBD [<a href="#rid4">4,5</a>]. This notion is supported by observed improvements in linear growth that occur after a variety of treatments that reduce inflammation in IBD, including exclusive enteral nutrition [<a href="#rid6">6,7</a>], <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> [<a href="#rid8">8-12</a>], <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">adalimumab</a> [<a href="#rid13">13-15</a>], or surgical resection [<a href="#rid16">16</a>]. The improvement in linear growth can be independent of weight gain or reductions in corticosteroid dose [<a href="#rid1">1,10</a>].</p><p></p><p class="bulletIndent1">Inflammation probably inhibits linear growth through proinflammatory cytokines, including tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-6. TNF-alpha appears to affect growth primarily by suppressing appetite [<a href="#rid17">17</a>], whereas IL-6 exerts direct effects on growth by inhibiting insulin-like growth factor 1 (IGF-1), which modulates the physiologic effects of growth hormone in a pattern suggestive of growth hormone resistance [<a href="#rid4">4,17-19</a>], and stimulating lipolysis [<a href="#rid20">20</a>]. Malnutrition also contributes to this suppression of the growth hormone-IGF-1 axis [<a href="#rid17">17</a>]. Interactions with genetic factors also have been suggested [<a href="#rid21">21-25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malnutrition</strong> – Both malnutrition and systemic inflammation reduce circulating IGF-1, a major mediator of growth failure in IBD [<a href="#rid26">26</a>]. Severe acute malnutrition is uncommon but occasionally occurs in children with Crohn disease. Several mechanisms contribute to malnutrition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insufficient nutrient intake</strong> – This is the most important contributor to malnutrition in IBD. Children with IBD often ingest less dietary energy compared with healthy children [<a href="#rid27">27</a>]. Nutrient intake may be particularly low during acute exacerbations of IBD. In one report, children with active Crohn disease were found to consume less energy than did those in remission [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2">Several mechanisms contribute to decreased intake, including anorexia (perhaps mediated by TNF-alpha, hypothalamic serotonin, and IL-1), the learned association of food with abdominal pain or diarrhea, and early satiety (possibly related to decreased gastric emptying [<a href="#rid29">29-32</a>]).</p><p></p><p class="bulletIndent2">Increased rates of disordered eating have been found among adolescents with IBD [<a href="#rid33">33</a>]. Further, a study of adult patients with IBD found that 17 percent were at risk for avoidant restrictive feeding disorder (ARFID), based on a screening questionnaire. Risk factors included active symptoms and inflammation, but 74 percent avoided foods even when in remission [<a href="#rid34">34</a>]. Those at risk for ARFID were more likely to be at risk for malnutrition. (See  <a class="medical medical_review" href="/z/d/html/2093.html" rel="external">"Eating disorders: Overview of epidemiology, clinical features, and diagnosis", section on 'Avoidant/restrictive food intake disorder'</a>.)</p><p></p><p class="bulletIndent2">In some cases, altered taste (eg, due to concomitant zinc deficiency [<a href="#rid35">35</a>] or medications, such as <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">metronidazole</a>) may decrease food intake [<a href="#rid36">36-39</a>]. In addition, some patients with IBD follow a restricted diet that can reduce caloric intake, although such dietary restrictions are unnecessary for most patients, except when prescribed as part of a specific regimen (eg, a specific exclusion diet). (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Other dietary changes'</a>.)</p><p></p><p class="bulletIndent2">Inadequate protein intake (or fecal protein losses) may affect muscle mass in growing children. Studies of children with Crohn disease demonstrated that increased protein intake resulted in increased nitrogen retention, increased amino acid incorporation into body protein stores, and decreased amino acid loss via oxidation [<a href="#rid40">40,41</a>]. Low protein intake is less likely to cause reduced muscle mass in adults, unless the deficiency is severe and prolonged (starvation).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maldigestion</strong> – Maldigestion (impaired processing of nutrients within the lumen of the gastrointestinal tract) is uncommon but occurs in some patients with complicated IBD. In particular, fat maldigestion (and subsequent malabsorption) can occur when there are reduced functional bile acids in the lumen, which can be caused by bacterial overgrowth, disease or resection of the terminal ileum, or use of <a class="drug drug_pediatric" data-topicid="13152" href="/z/d/drug information/13152.html" rel="external">cholestyramine</a>. Maldigestion also can occur among patients with Crohn disease who have extensive mucosal disease, chronic liver dysfunction (eg, sclerosing cholangitis), extensive small bowel resections, or enteroenteric fistulas. In patients with extensive resections or enteroenteric fistulas, ingested nutrients may have insufficient exposure to digestive secretions and enzymes, leading to maldigestion. (See  <a class="medical medical_review" href="/z/d/html/4781.html" rel="external">"Overview of nutrient absorption and etiopathogenesis of malabsorption", section on 'Causes of fat malabsorption'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fecal nutrient losses</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Carbohydrates</strong> – Whether there is a greater incidence of lactose intolerance among children with IBD has not been established. Some studies suggest that the prevalence of lactose malabsorption in individuals with Crohn disease may be somewhat higher than in the general population due to small bowel inflammation and enterocyte damage or due to bacterial overgrowth [<a href="#rid42">42</a>]. However, more recent data suggest that there is no difference when compared with controls [<a href="#rid42">42-45</a>]. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent3">If lactose intolerance is present, it can contribute to gastrointestinal symptoms but rarely causes clinically important energy loss because a portion of malabsorbed carbohydrates is fermented then usually reabsorbed in the colon (unless concomitant antibiotics or colonic disease interfere with this process).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fats</strong> – Historically, fat malabsorption was seen in approximately 30 percent of patients with Crohn disease [<a href="#rid46">46-48</a>]. The cause is multifactorial, including maldigestion (discussed above), small bowel inflammation, or decreased bowel length due to surgery. With modern treatment modalities that prevent or reverse these processes, clinically significant fat malabsorption is probably uncommon. When present, fat malabsorption substantially reduces energy absorption and contributes to growth failure.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Proteins</strong> – Capillary leak within inflamed tissue may result in protein loss. This is the main cause of reduced serum albumin concentrations that are commonly seen in active Crohn disease and, to a lesser extent, in ulcerative colitis. Fecal alpha-1 antitrypsin serves as a measure of intestinal protein loss and has been shown to reflect disease activity in IBD [<a href="#rid49">49,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased energy expenditure</strong> – Differences in resting energy expenditure (REE) do not contribute significantly to malnutrition in pediatric IBD. REE in well-nourished children with Crohn disease is not different from values of healthy children [<a href="#rid36">36</a>]. Furthermore, REE in children with Crohn disease does not differ between active or inactive disease, based on clinical activity index scores or inflammatory markers (eg, lactoferrin, erythrocyte sedimentation rate, C-reactive protein) [<a href="#rid51">51,52</a>]. In malnourished children with IBD, older studies reported an apparent increase in REE, but this was likely a spurious finding related to efforts to correct for differences in body composition (ie, expressing REE per unit of lean body mass) [<a href="#rid51">51,53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadism</strong> – Hypogonadism and pubertal delay are common in children with active IBD and contribute to their decreased linear growth and delayed accretion of lean body mass compared with healthy children of the same age [<a href="#rid17">17</a>]. (See <a class="local">'Clinical manifestations'</a> below and  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty"</a>.)</p><p></p><p class="bulletIndent1">Because children with pubertal delay usually have delayed bone age, they may experience some catch-up growth after the onset of puberty, particularly if they have adequate nutrition and well-controlled disease. By contrast, patients with prolonged inflammatory disease, malnutrition, or corticosteroid therapy during puberty may not experience full catch-up growth before the epiphyses close, resulting in compromised adult height [<a href="#rid55">55</a>]. (See <a class="local">'Impaired growth'</a> below.)</p><p></p><p class="bulletIndent1">Hypogonadism is probably caused by both inflammatory processes and malnutrition [<a href="#rid56">56</a>]. Proinflammatory cytokines directly reduce gonadal sex steroid production and perhaps also androgen and estrogen receptor expression in peripheral tissues [<a href="#rid4">4,57,58</a>]. In addition, healthy body weight is an important prerequisite for the onset of puberty. Leptin levels, which are proportionate to body fat, must be sufficient for maturation of the gonadotropin-releasing hormone axis. (See  <a class="medical medical_review" href="/z/d/html/5849.html" rel="external">"Normal puberty", section on 'Weight and body composition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid effects</strong> – Glucocorticoids may contribute to growth failure, particularly when used during puberty [<a href="#rid59">59,60</a>]. Glucocorticoids interfere with endogenous growth hormone secretion and action and disrupt metabolic processes essential for normal growth, including bone formation, nitrogen retention, and collagen formation [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature", section on 'Glucocorticoid therapy'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3780126599"><span class="h2">Impaired growth</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired weight gain</strong> – IBD is associated with impaired weight gain, which is often present at diagnosis  (<a class="graphic graphic_figure graphicRef139270" href="/z/d/graphic/139270.html" rel="external">figure 1</a>). As an example, in a series of children with newly diagnosed Crohn disease, weight loss was reported in 58 percent and weight was &lt;10<sup>th</sup> percentile in 32 percent and &lt;3<sup>rd</sup> percentile in 27 percent [<a href="#rid61">61</a>]. Among those with ulcerative colitis, weight loss was reported in 31 percent and weight was &lt;10<sup>th</sup> percentile in 15 percent and &lt;3<sup>rd</sup> percentile in 9 percent. Similarly, in a large study of North American children with newly diagnosed IBD, low body mass index (BMI; &lt;5<sup>th</sup> percentile) was found in 22 to 24 percent of children with Crohn disease and 7 to 9 percent of those with ulcerative colitis [<a href="#rid62">62</a>]. However, 10 percent of children with Crohn disease and 20 to 30 percent of those with ulcerative colitis had an elevated BMI at diagnosis, reflecting population trends in childhood obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced muscle mass</strong> – Children with Crohn disease typically have lower lean body mass than height-matched unaffected individuals, particularly in the active phase of disease. In a systematic review including 1479 children with IBD, 93.6 percent of patients with Crohn disease and 47.7 percent of those with ulcerative colitis showed deficits in lean mass when compared with healthy controls [<a href="#rid60">60,63,64</a>]. Patients who have lost between 5 and 10 percent of their lean body mass usually have no clinical sequelae. However, loss of lean body mass beyond this threshold is associated with increased morbidity. Children are particularly susceptible to these effects.</p><p></p><p class="bulletIndent1">The primary mediators of this effect are inflammation (excessive catabolism, which accelerates protein breakdown), decreased physical activity, corticosteroid treatment [<a href="#rid65">65-67</a>], and, possibly, inadequate protein intake. (See <a class="local">'Pathogenesis of growth failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear growth delay</strong> – Linear growth is easily disrupted by inflammation and malnutrition, and growth failure is common in children with Crohn disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short stature at diagnosis</strong> – In population-based studies of children with Crohn disease, 6 to 13 percent present with short stature (height &lt;3<sup>rd</sup> percentile or Z-score &lt;-2) [<a href="#rid5">5,22,61,68</a>]. In a large multicenter Canadian study of children with Crohn disease, each month of diagnostic delay was associated with progressive decreases in height-for-age Z-score [<a href="#rid69">69</a>]. Among children with ulcerative colitis, approximately 3 percent present with short stature, which is similar to the general population [<a href="#rid1">1,22,61,70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Height velocity</strong> – Height velocity, determined by serial measures of height, is a particularly sensitive measure of growth failure [<a href="#rid71">71</a>]. Reduced height velocity is present at diagnosis in 60 to 90 percent of children with Crohn disease  (<a class="graphic graphic_figure graphicRef139270" href="/z/d/graphic/139270.html" rel="external">figure 1</a>), and marked growth delays occur in 20 to 30 percent at some time during their illness [<a href="#rid22">22,70,72,73</a>]. Height differences are more pronounced in males [<a href="#rid74">74</a>]. Approximately 5 percent of children presenting with Crohn disease have growth failure as their sole presenting complaint [<a href="#rid75">75</a>], and up to 40 percent have significantly delayed bone age [<a href="#rid76">76,77</a>]. For children with ulcerative colitis, decreased height velocity is present at diagnosis in approximately 10 to 25 percent [<a href="#rid1">1,22,61,70</a>]. (See <a class="local">'Routine monitoring of growth and puberty'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Response to treatment</strong> – Whether growth failure improves after diagnosis depends upon the degree/extent of disease involvement, the child's stage of skeletal development (eg, bone age or stage of puberty), and timing and type of treatment. The association between timing of disease onset and growth effects are complex: On one hand, early onset of disease that attenuates the pubertal growth spurt is more likely to have effects on growth compared with later disease onset [<a href="#rid78">78</a>]. On the other hand, initiation of effective treatment before epiphyseal closure can permit catch-up growth.</p><p></p><p class="bulletIndent2">Treatment with enteral nutrition [<a href="#rid27">27,79,80</a>] or biologic agents [<a href="#rid9">9,13,81</a>] is particularly effective in improving linear growth. The mechanisms for these effects may include improvements in nutrition, reduction in inflammation, and avoidance of or reduction in glucocorticoid use. By contrast, in older studies of children with Crohn disease, in which treatment tended to rely on glucocorticoids and immunomodulators, growth failure often persisted [<a href="#rid22">22,68,70</a>]. (See <a class="local">'Pathogenesis of growth failure'</a> above and <a class="local">'With active IBD'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adult stature</strong> – Because of persistent disruptions of linear growth during childhood, some patients with Crohn disease have reduced adult stature. A study of young adults diagnosed with Crohn disease prior to age 16 calculated a height deficit of 2.4 cm compared with estimated target heights [<a href="#rid82">82</a>]. For almost 20 percent of the subjects, the height deficit was more than 8 cm. In more recent studies, in which treatment often included enteral nutrition or biologic agents, short stature was reported in approximately 6 percent of patients at maximal follow-up and approximately 20 to 30 percent of patients did not reach their target height [<a href="#rid5">5,22,83</a>]. The effect of disease on adult height is somewhat mitigated because they tend to have delayed bone age and thus often continue to grow beyond the time of expected growth plate closure. In one study, 80 percent of pediatric patients with IBD demonstrated continued growth of 1.3 to 1.6 cm beyond the time of expected growth plate closure [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H2009406841"><span class="h2">Pubertal delay</span><span class="headingEndMark"> — </span>Pubertal delay is common and depends on the age of onset of IBD. In one series of 11 females with early-onset Crohn disease, 75 percent had menarche at 16 years of age or later [<a href="#rid85">85</a>]. Pubertal delay was much less common in children with ulcerative colitis. Other series report average delays in puberty onset of approximately 1.5 years for females and 0.8 years for males [<a href="#rid86">86,87</a>].</p><p>Pubertal delay can contribute to growth failure, psychosocial stress, and reduced bone mineral density. However, it is also associated with delayed epiphyseal closure, which may permit catch-up growth in some cases. Interventions to treat the underlying disease activity and improve nutrition are the first-line therapies and are generally successful. For selected patients, adjunctive treatment with sex steroids may be appropriate. (See <a class="local">'Management of growth failure and pubertal delay'</a> below and <a class="local">'Other interventions'</a> below.)</p><p>Pubertal delay in IBD is mediated by both malnutrition and inflammation and appears to involve both central (hypogonadotropic) and peripheral hypogonadism [<a href="#rid17">17</a>]. (See <a class="local">'Pathogenesis of growth failure'</a> above.)</p><p class="headingAnchor" id="H1115105639"><span class="h2">Other comorbidities</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone disease</strong> – Children and adolescents with IBD tend to have reduced bone mineral density [<a href="#rid88">88,89</a>]. This is more common among those with Crohn disease than those with ulcerative colitis and may be present at diagnosis [<a href="#rid90">90,91</a>]. Bone disease (osteoporosis and/or osteomalacia) is a common problem in adults with IBD, and the rate does not differ among patients with Crohn disease compared with those with ulcerative colitis [<a href="#rid92">92</a>]. Risk factors for bone disease include corticosteroid use, disease activity, pubertal delay, and, possibly, deficiencies of calcium and vitamins D and K [<a href="#rid93">93-96</a>]. (See  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1">It is unclear whether modest decreases in bone density predict fracture risk [<a href="#rid96">96</a>], and limited information is available to guide management. Nonetheless, because of the high frequency of bone disease in adult patients with IBD and its effects on quality of life, we recommend close attention to bone health throughout life. Prevention, monitoring, and treatment of bone disease in children and adolescents with IBD are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative morbidity</strong> – Malnutrition is a risk factor for complications after surgery for IBD. As examples, among children requiring first-stage surgical therapy for ulcerative colitis, low serum albumin and preoperative corticosteroid use were predictors for postoperative infection, although preoperative BMI was not [<a href="#rid97">97</a>]. Similarly, a study in adults undergoing surgery for Crohn disease found that poor nutritional status was a risk factor for intraabdominal septic complications [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial stress</strong> – Children with IBD are at increased risk for anxiety and depression, with a prevalence of approximately 22 percent [<a href="#rid99">99</a>]. The causes are multifactorial and often relate to disease activity, but short stature, pubertal delay, and associated body image dissatisfaction may also be contributors in some cases. Screening for psychosocial stress is recommended in children with IBD [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Psychological screening and support'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Routine monitoring of growth and puberty is essential for the care of children with IBD. Prompt recognition of impaired growth allows for intervention to optimize nutrition, suppress inflammation, and restore healthy growth and pubertal development.</p><p class="headingAnchor" id="H21"><span class="h2">Routine monitoring of growth and puberty</span><span class="headingEndMark"> — </span>All children with IBD should have regular measurements of body weight, height, and pubertal status  (<a class="graphic graphic_algorithm graphicRef139480" href="/z/d/graphic/139480.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,71</a>]. In our practice, we perform these measurements at least every four months for patients with quiescent disease and more frequently for those with active disease or evidence of growth failure  (<a class="graphic graphic_table graphicRef61093" href="/z/d/graphic/61093.html" rel="external">table 1</a>). Reduced linear growth is often first noted by a decreasing trend in height percentiles on a standard height-for-age chart  (<a class="graphic graphic_figure graphicRef139270" href="/z/d/graphic/139270.html" rel="external">figure 1</a>).</p><p>The child's growth and puberty are then assessed with the following derived measures:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Height velocity</strong> – Height velocity measurements are the most sensitive parameter for detection of growth abnormalities during IBD in children [<a href="#rid71">71,73</a>]. Height velocity can be calculated from two or more serial measurements of height, ideally taken three to six months apart and expressed as growth in cm/year. Any child older than two years whose height velocity is less than 4 cm/year probably has growth failure because at least 95 percent of healthy children grow faster than 4 cm/year [<a href="#rid101">101</a>]. During puberty, peak height velocity is 6 to 12 cm/year in boys and 5 to 10 cm/year in girls. (See  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Is the child's height velocity impaired?'</a>.)</p><p></p><p class="bulletIndent1">To determine if a child's height velocity is appropriate for age, calculate the height velocity (in cm/year) and plot the result on a standard curve  (<a class="graphic graphic_figure graphicRef96367 graphicRef96366" href="/z/d/graphic/96367.html" rel="external">figure 2A-B</a>). Height velocity below the 10<sup>th</sup> percentile warrants additional assessment of nutrition and IBD management (see <a class="local">'Additional evaluation for children with growth failure'</a> below). A child's height and height velocity should also be interpreted in the context of their genetic potential, which is usually estimated based on the midparental height. (See  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Prediction of adult height'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body mass index (BMI)</strong> – Determine the age-specific percentiles for BMI by plotting on a standard chart  (<a class="graphic graphic_figure graphicRef60784 graphicRef68478" href="/z/d/graphic/60784.html" rel="external">figure 3A-B</a>) or by using a calculator for males (<a class="calc calc_professional" href="/z/d/html/13412.html" rel="external">calculator 1</a>) or for females (<a class="calc calc_professional" href="/z/d/html/13415.html" rel="external">calculator 2</a>). For children with progressive decreases in BMI percentiles or a BMI below the 10<sup>th</sup> percentile for age, we perform further evaluation of nutrition and IBD management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pubertal timing and progression</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sexual maturity rating</strong> – At each visit, determine the patient's sexual maturity rating, also known as Tanner staging. In females, the earliest signs of pubertal development in females are the appearance of breast buds  (<a class="graphic graphic_picture graphicRef72038 graphicRef79782" href="/z/d/graphic/72038.html" rel="external">picture 1A-B</a>). In males, the earliest sign is a testicular volume of greater than or equal to 4 mL  (<a class="graphic graphic_picture graphicRef80005" href="/z/d/graphic/80005.html" rel="external">picture 2</a>), corresponding to approximately 2.0 to 3.1 cm in testicular length.</p><p></p><p class="bulletIndent2">Other key milestones are the pubertal growth spurt (normally at approximately 10 to 13 years in females and 12 to 15 years in males) and menarche in females. Growth potential is limited after menarche. (See  <a class="medical medical_review" href="/z/d/html/5849.html" rel="external">"Normal puberty"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pubertal progression</strong> – Using serial measurements or reported history, determine if puberty is delayed or stalled (see  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty"</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Delayed puberty is defined as the absence of pubertal onset by an age 2 to 3 standard deviations above the mean age of pubertal onset for the relevant population. In the United States, this corresponds to an upper limit of approximately 12 to 13 years for females and approximately 13 to 14 years for males.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stalled puberty refers to abnormally slow pubertal progression after pubertal onset, eg, no significant pubertal progression for two or more years.</p><p></p><p class="bulletIndent2">Children with pubertal delay may warrant additional attention even before the above thresholds are reached. This may include optimizing nutrition and IBD management, avoiding glucocorticoid therapy, and close monitoring of puberty (eg, through referral to an endocrine or adolescent medicine specialist). (See <a class="local">'Management of growth failure and pubertal delay'</a> below.)</p><p></p><p class="headingAnchor" id="H2876100697"><span class="h2">Additional evaluation for children with growth failure</span><span class="headingEndMark"> — </span>More detailed evaluation is warranted for children with delayed growth (eg, height velocity or BMI &lt;10<sup>th</sup> percentile for age) or delayed puberty, including the following measures:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone age determination</strong> – For children with growth failure, radiographic determination of bone age is a valuable component of the evaluation because it helps to determine the severity of the growth deficit as well as residual growth potential. Results are abnormal in up to 40 percent of children with IBD [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Bone age determination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional assessment</strong> – In our practice, we perform a structured assessment of dietary intake in children who are not gaining weight appropriately and if the mechanism is unclear. For these children, the assessment can help determine whether the problem is related to inadequate caloric intake versus malabsorption. For other children, we find that formal assessments rarely contribute to clinical decision-making because poor weight gain in IBD is generally mediated by reduced appetite and thus does not readily respond to dietary modification. Despite this limitation, some experts perform periodic structured dietary assessment (eg, twice a year in younger patients and once a year in adolescents), as suggested in a European guideline [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1">When a structured dietary assessment is undertaken, it generally is based on a dietary recall or log for a three- to five-day period, with calculation of total calories, protein, and micronutrients consumed. These estimates are then compared with recommended nutrient intakes for the child's age group, adjusted for physical activity level and catch-up growth. (See  <a class="medical medical_review" href="/z/d/html/5357.html" rel="external">"Dietary history and recommended dietary intake in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Micronutrient deficiencies</strong> – Laboratory evaluation for micronutrient deficiencies is appropriate at the initial diagnosis of IBD and also for children with growth failure. The selection of tests depends upon the patient's overall nutritional status and disease activity and location, as outlined in the table  (<a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone density</strong> – There are no widely accepted standards for monitoring bone health in children and adolescents with IBD, and practice varies regarding routine monitoring. However, we suggest obtaining baseline densitometry (dual-energy x-ray absorptiometry [DXA]) in patients with risk factors for bone disease, including those with growth failure, secondary or primary amenorrhea, pubertal delay, refractory IBD, prolonged use of glucocorticoids, or a history of clinically significant fractures. Monitoring and management of bone mineral density in this population are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body composition</strong> – BMI measurement alone is usually a sufficient index of body composition for clinical decision-making. While BMI does not directly measure body composition, it is correlated with both adiposity and lean body mass.</p><p></p><p class="bulletIndent1">Direct measures of body composition are generally not necessary or helpful for clinical practice. These include triceps skinfold thickness measurements (reflecting body fat) and midarm cross-sectional area (reflecting lean body mass). DXA provides an accurate and direct measurement of body composition, but its main clinical use in children with IBD is to measure bone density [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/5363.html" rel="external">"Measurement of body composition in children"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>All individuals with IBD should be given dietary advice to encourage a balanced diet with adequate calories to optimize growth [<a href="#rid71">71</a>]. For patients with active disease or malabsorption, energy intake goals will often be higher than for the general population.</p><p>To optimize energy intake, we avoid dietary restrictions for most patients. There is no good evidence that dietary restrictions are beneficial, except as part of carefully supervised nutritional therapy for IBD (eg, exclusive enteral nutrition) or when needed to address specific problems (eg, limiting dairy products in patients with lactose intolerance or limiting fiber in patients with intestinal strictures) [<a href="#rid71">71</a>]. A notable exception is certain specific carbohydrate diets, which show some promise when used with close clinical guidance and, sometimes, in conjunction with partial enteral nutrition. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Other dietary changes'</a>.)</p><p>For all patients, we minimize the use of glucocorticoids because of their adverse effects on growth and bone health [<a href="#rid1">1</a>]. These adverse effects of glucocorticoids must be balanced against their potential therapeutic value.</p><p class="headingAnchor" id="H2350595015"><span class="h1">MANAGEMENT OF GROWTH FAILURE AND PUBERTAL DELAY</span><span class="headingEndMark"> — </span>The goals of treatment include correction of malnutrition and normalization of linear growth and pubertal development [<a href="#rid102">102</a>]. This requires both optimizing nutrition and effectively treating the underlying inflammatory disease process. The intensity of the intervention can be adjusted to the severity of the growth failure. Prompt and comprehensive intervention is particularly important if a child has marked growth failure near the end of puberty (eg, around menarche) because such children have limited time left to grow before epiphyseal closure. (See <a class="local">'Pathogenesis of growth failure'</a> above.)</p><p>Initial steps depend on the severity of growth failure and disease activity  (<a class="graphic graphic_algorithm graphicRef139480" href="/z/d/graphic/139480.html" rel="external">algorithm 1</a>):</p><p class="headingAnchor" id="H165685303"><span class="h2">Patients with mild growth failure or pubertal delay without active IBD</span><span class="headingEndMark"> — </span>For patients with mild growth failure (eg, decreased height velocity) and/or pubertal delay, the initial intervention is to provide focused dietary advice to increase energy intake, which may include adding liquid supplements (formulated as shakes or puddings). Children with growth failure also have increased energy requirements for catch-up growth, even if their IBD is inactive. Catch-up growth typically requires 125 to 150 percent of the recommended daily allowance for energy and 2.4 to 3 g/kg per day of protein [<a href="#rid71">71,103</a>]. (See  <a class="medical medical_review" href="/z/d/html/5357.html" rel="external">"Dietary history and recommended dietary intake in children"</a> and  <a class="medical medical_review" href="/z/d/html/2845.html" rel="external">"Normal growth patterns in infants and prepubertal children", section on 'Ideal body weight'</a>.)</p><p>The efficacy of nutritional counseling in IBD has not been carefully studied, and the energy and nutrient increases achieved through dietary counseling are probably modest. Addition of a liquid supplement taken by mouth supplying 35 to 50 percent of estimated energy needs effectively promotes weight gain [<a href="#rid104">104,105</a>].</p><p>In addition, the use of <a class="drug drug_pediatric" data-topicid="13194" href="/z/d/drug information/13194.html" rel="external">cyproheptadine</a> as an appetite stimulant can be considered. While this has not specifically been studied in a group of children with IBD, it has been proven effective in children with cystic fibrosis, growth hormone deficiency, and cancer. The main reported side effect is sedation [<a href="#rid106">106</a>].</p><p>Children who do not respond to this intervention, or those with clearly adequate intake, should be reevaluated for the possibility of occult IBD activity and for other causes of growth failure (eg, familial short stature or constitutional delay of growth and puberty, which are variants of normal growth). (See  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature"</a>.)</p><p class="headingAnchor" id="H2453658656"><span class="h2">Patients with marked growth failure or pubertal delay</span><span class="headingEndMark"> — </span>Effective treatment of the inflammatory process itself is critical to restoring growth. As a result, children with marked growth failure should undergo a thorough assessment of IBD activity (which may be occult). This may include laboratory testing and endoscopic evaluation.</p><p class="headingAnchor" id="H5724868"><span class="h3">With active IBD</span><span class="headingEndMark"> — </span>For patients with marked growth failure <strong>and</strong> evidence of active IBD (which may be occult), management includes optimizing nutrition and initiating or escalating IBD treatment to address the underlying inflammatory disease process.</p><p>For children with Crohn disease, the primary options are (see  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclusive enteral nutrition</strong> – Exclusive enteral nutrition (enteral nutrition with no food taken by mouth) is an important option for primary therapy for Crohn disease and is especially valuable in children with primarily small intestinal disease and growth failure. Small randomized trials indicate that exclusive enteral nutrition suppresses inflammation, promotes mucosal healing, and reverses growth failure in children with IBD. This approach is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Exclusive enteral nutrition'</a>.)</p><p></p><p class="bulletIndent1">An alternate approach with promising preliminary evidence is partial enteral nutrition with a rigorously administered specific exclusion diet. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Partial enteral nutrition with specific exclusion diet'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic agents</strong> – Marked growth failure is considered a symptom of moderate or severe Crohn disease and is thus an indication for biologic therapy with <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">adalimumab</a> [<a href="#rid8">8,9,13,107</a>]. These therapies have the greatest benefits on growth when initiated at earlier stages of puberty (ie, Tanner stage 1 to 3) [<a href="#rid12">12</a>]. The benefit of these and other biologic therapies on growth is probably due to their antiinflammatory effects rather than to reductions in corticosteroid use. (See  <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents", section on 'First-line biologic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – In children with localized treatment-resistant Crohn disease or refractory colonic IBD, surgical resection of the inflamed bowel segment can be effective in restoring growth [<a href="#rid108">108,109</a>]. These observations further suggest that effective treatment of the inflammatory process is a critical component of treatment for growth failure in IBD. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulators</strong> – Thiopurines (<a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a> or <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">6-mercaptopurine</a>) appear to have little or no effect on growth. A randomized trial of early treatment with 6-mercaptopurine did not show beneficial effects on growth compared with conventional treatment with glucocorticoids, but the sample size was small and the subjects had minimal growth retardation at randomization [<a href="#rid110">110</a>]. Moreover, an observational study reported that treatment with thiopurines was negatively associated with several anthropometric measures [<a href="#rid111">111</a>].</p><p></p><p>Similarly, children with ulcerative colitis complicated by growth failure or pubertal delay require reassessment and optimization of disease management. (See  <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">"Management of mild to moderate ulcerative colitis in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H2694633211"><span class="h3">Without active IBD</span><span class="headingEndMark"> — </span>Patients with marked growth failure and/or pubertal delay and <strong>no</strong> evidence of active IBD (after careful reevaluation) should be evaluated for other causes; referral to a pediatric endocrinologist may be appropriate (see  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature"</a>). If no specific cause is identified and the child is unable to voluntarily increase their energy intake, we suggest a trial of nocturnal enteral feeding (partial enteral nutrition).</p><p>When this approach is used, the child usually eats freely during the day and then passes a nasogastric tube at night to administer formula while sleeping. Nutritional goals for total intake are generally from 100 to 150 percent of the recommended daily allowances for height-age for both energy (85 to 90 kCal/kg per day) and protein (2.4 to 3.0 g/kg per day). This usually translates to 1000 to 1500 kCals of formula nightly, depending on the child's weight and typical daytime food intake. Initially, smaller supplementary caloric goals can be used (500 to 1000 kcals) to judge tolerability. Based on weight gain over time, the calories are adjusted. If volume/rate is a limiting factor, formulas with higher caloric density can be used. If the child is severely malnourished, it may be prudent to initiate therapy in the hospital and monitor for refeeding syndrome, which is characterized by low levels of phosphorus, potassium, and magnesium developing during the first one to two weeks of refeeding.</p><p>The easiest and most successful approach is to administer a set amount of formula each night rather than calculating the target volume each night based on the child's observed food intake. Deficiencies in vitamins and minerals should be assessed and replaced by supplementation [<a href="#rid112">112</a>]. The type of formula used (elemental versus polymeric) is not important [<a href="#rid71">71</a>]. This issue has been best examined in the setting of exclusive enteral nutrition, which is discussed below.</p><p>Benefits of this approach were seen in a small nonrandomized study of prepubertal children with Crohn disease, in which nocturnal feedings yielded a mean weight gain of 11.75 kg and a mean height gain of 6.98 cm over one year, whereas matched control subjects had no significant change in weight and height [<a href="#rid113">113</a>]. Another observational study reported improved weight gain and height velocity among children treated with intermittent nocturnal supplemental feeds (administered one out of every four months) [<a href="#rid114">114</a>]. A third study, performed retrospectively, suggested that use of supplementary nasogastric feeds during remission of IBD improved linear growth and prolonged remission [<a href="#rid115">115</a>]. Supplemental feeds typically increase intakes of energy, calcium, and vitamin D, which help to prevent and treat bone disease. (See  <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a>.)</p><p>Partial enteral nutrition has also been used in conjunction with a specific Crohn disease exclusion diet. This is a highly structured approach intended as a primary therapy to induce mucosal healing in Crohn disease (similar to exclusive enteral nutrition). The limited evidence is summarized separately. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Partial enteral nutrition with specific exclusion diet'</a>.)</p><p class="headingAnchor" id="H32"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Optimization of nutrition and control of the underlying IBD using intensive therapies are imperative prior to considering any endocrine therapy [<a href="#rid17">17</a>].</p><p>A few reports describe treatment of children with IBD and severe growth delay with <a class="drug drug_pediatric" data-topicid="13354" href="/z/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> [<a href="#rid116">116-121</a>], but there is insufficient information to recommend for or against this approach in this population.</p><p>For children with marked pubertal delay, judicious adjunctive treatment with sex steroids may be appropriate but must be balanced against the risk of growth attenuation by accelerating epiphysial closure. Small case series have described the use of testosterone supplementation in boys with IBD and pubertal delay; however, this is not a mainstay of treatment [<a href="#rid122">122</a>]. The use of estrogen to induce menarche has not been reported in this population. (See  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Hormonal therapy'</a>.)</p><p class="headingAnchor" id="H853229998"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">"Society guideline links: Inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H370442007"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86458.html" rel="external">"Patient education: Ulcerative colitis in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86454.html" rel="external">"Patient education: Crohn disease in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impaired growth</strong> – Disruption of linear growth is common in children with inflammatory bowel disease (IBD) and particularly those with Crohn disease. Marked growth delays occur in 20 to 30 percent of children with Crohn disease. Linear growth is highly sensitive to disease activity. (See <a class="local">'Impaired growth'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pubertal delay</strong> – Crohn disease can interfere with pubertal onset (causing delayed puberty) and/or progression (causing stalled puberty). (See <a class="local">'Pubertal delay'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – A combination of factors contributes to the pathogenesis of growth failure in IBD, including inadequate dietary intake, inflammation, malabsorption, glucocorticoids, and hypogonadism. The hypogonadism is, in turn, mediated by both malnutrition and inflammation. (See <a class="local">'Pathogenesis of growth failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine monitoring</strong> – All children with IBD should have regular measurements of body weight, height, and pubertal status. Body mass index (BMI) and height velocity should be calculated  (<a class="graphic graphic_table graphicRef61093" href="/z/d/graphic/61093.html" rel="external">table 1</a>). (See <a class="local">'Routine monitoring of growth and puberty'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional evaluation for those with growth failure</strong> – Children with IBD whose height velocity  (<a class="graphic graphic_figure graphicRef96367 graphicRef96366" href="/z/d/graphic/96367.html" rel="external">figure 2A-B</a>) or BMI  (<a class="graphic graphic_figure graphicRef60784 graphicRef68478" href="/z/d/graphic/60784.html" rel="external">figure 3A-B</a>) is below the 10<sup>th</sup> percentile for age are probably experiencing growth failure due to their disease. Similarly, delayed or stalled puberty in this population is likely caused by the underlying disease. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent2">These children should be further assessed for nutritional deficits and IBD activity (which may be occult). Radiographic determination of bone age is a valuable component of the evaluation because it helps to determine the severity of the growth deficit as well as residual growth potential. These children should also undergo laboratory evaluation for micronutrient deficiencies  (<a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">table 2</a>). (See <a class="local">'Additional evaluation for children with growth failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – All children with IBD should be counseled to ensure a balanced diet with adequate dietary energy and nutrients to optimize growth. For patients with active disease, malabsorption, or growth failure, energy and nutrient goals will often be higher than for the general population. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management depends upon the severity of growth failure and IBD activity  (<a class="graphic graphic_algorithm graphicRef139480" href="/z/d/graphic/139480.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild growth failure without active IBD</strong> – Nutritional counseling to increase energy and nutrient intake is generally sufficient for these patients. Interventions may include adding liquid supplements (formulated as shakes or puddings) to the diet. Those who do not respond, or those with clearly adequate intake, should be reevaluated for the possibility of occult IBD activity and for other causes of growth failure. (See <a class="local">'Patients with mild growth failure or pubertal delay without active IBD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Marked growth failure</strong> – Patients with marked growth failure should undergo a thorough assessment of IBD activity, which may be occult.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>With active IBD</strong> – For patients in this category, management includes optimizing nutrition and initiating or escalating treatment to address the underlying inflammatory process (see <a class="local">'With active IBD'</a> above):</p><p></p><p class="bulletIndent3">For patients with Crohn disease, this generally consists of a biologic agent (<a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">adalimumab</a>) or exclusive enteral nutrition. Surgical treatment may be required for those with localized treatment-resistant disease. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Moderate or severe'</a>.)</p><p></p><p class="bulletIndent3">For patients with ulcerative colitis, the choice of treatment depends upon the extent of disease, severity of symptoms, and response to initial treatment. Details of initiating and escalating therapy for patients with ulcerative colitis are provided separately. (See  <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">"Management of mild to moderate ulcerative colitis in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Without active IBD</strong> – Patients in this category should be evaluated for other causes of growth failure. If no specific cause is identified and the child is unable to voluntarily increase their energy intake, we suggest a trial of nocturnal enteral feeding (partial enteral nutrition) rather than other interventions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Without active IBD'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:839.</a></li><li><a class="nounderline abstract_t">Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17:1314.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Andrews H, et al. Clinical Variables Associated With Statural Growth in Pediatric Crohn's Disease Differ by Sex (The Growth Study). Inflamm Bowel Dis 2021; 27:751.</a></li><li><a class="nounderline abstract_t">Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006; 43:144.</a></li><li><a class="nounderline abstract_t">Ley D, Duhamel A, Behal H, et al. Growth Pattern in Paediatric Crohn Disease Is Related to Inflammatory Status. J Pediatr Gastroenterol Nutr 2016; 63:637.</a></li><li><a class="nounderline abstract_t">Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; :CD003873.</a></li><li><a class="nounderline abstract_t">Sohouli MH, Fatahi S, Farahmand F, et al. Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease. Aliment Pharmacol Ther 2022; 56:384.</a></li><li><a class="nounderline abstract_t">Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863.</a></li><li><a class="nounderline abstract_t">Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13:424.</a></li><li><a class="nounderline abstract_t">Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52:31.</a></li><li><a class="nounderline abstract_t">Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383.</a></li><li><a class="nounderline abstract_t">Cameron FL, Altowati MA, Rogers P, et al. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017; 64:47.</a></li><li><a class="nounderline abstract_t">Walters TD, Faubion WA, Griffiths AM, et al. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease. Inflamm Bowel Dis 2017; 23:967.</a></li><li><a class="nounderline abstract_t">Pichler J, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol 2015; 21:6613.</a></li><li><a class="nounderline abstract_t">Rinawi F, Popalis C, Tersigni C, et al. Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease: Associations With Adalimumab Exposure. J Pediatr Gastroenterol Nutr 2022; 74:389.</a></li><li><a class="nounderline abstract_t">Hojsak I, Kolacek S, Hansen LF, et al. Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease--a multicenter European study. J Pediatr Surg 2015; 50:1630.</a></li><li><a class="nounderline abstract_t">Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth retardation in paediatric inflammatory bowel disease. Paediatr Drugs 2014; 16:29.</a></li><li><a class="nounderline abstract_t">Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46:694.</a></li><li><a class="nounderline abstract_t">Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A 2005; 102:13260.</a></li><li><a class="nounderline abstract_t">Yang Y, Ju D, Zhang M, Yang G. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 2008; 33:261.</a></li><li><a class="nounderline abstract_t">D'Mello S, Trauernicht A, Ryan A, et al. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm Bowel Dis 2012; 18:236.</a></li><li><a class="nounderline abstract_t">Ishige T. Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 2019; 8:16.</a></li><li><a class="nounderline abstract_t">Lee JJ, Essers JB, Kugathasan S, et al. Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study. Ann Hum Genet 2010; 74:489.</a></li><li><a class="nounderline abstract_t">Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006; 55:1114.</a></li><li><a class="nounderline abstract_t">Levine A, Shamir R, Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am J Gastroenterol 2005; 100:1598.</a></li><li><a class="nounderline abstract_t">Chouliaras G, Mantzou A, Margoni D, et al. Body height in paediatric inflammatory bowel diseases: A structural equation model analysis. Eur J Clin Invest 2018; 48:e12969.</a></li><li><a class="nounderline abstract_t">Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:75.</a></li><li><a class="nounderline abstract_t">Pons R, Whitten KE, Woodhead H, et al. Dietary intakes of children with Crohn's disease. Br J Nutr 2009; 102:1052.</a></li><li><a class="nounderline abstract_t">Keller J, Binnewies U, Rösch M, et al. Gastric emptying and disease activity in inflammatory bowel disease. Eur J Clin Invest 2015; 45:1234.</a></li><li><a class="nounderline abstract_t">Nóbrega AC, Ferreira BR, Oliveira GJ, et al. Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease. BMC Gastroenterol 2012; 12:175.</a></li><li><a class="nounderline abstract_t">Ballinger A, El-Haj T, Perrett D, et al. The role of medial hypothalamic serotonin in the suppression of feeding in a rat model of colitis. Gastroenterology 2000; 118:544.</a></li><li><a class="nounderline abstract_t">El-Haj T, Poole S, Farthing MJ, Ballinger AB. Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin. Brain Res 2002; 927:1.</a></li><li><a class="nounderline abstract_t">David JG, Chute D, Reed B, et al. Assessing the Prevalence of and Risk Factors for Disordered Eating Attitudes and Behaviors in Adolescents With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022; 28:143.</a></li><li><a class="nounderline abstract_t">Yelencich E, Truong E, Widaman AM, et al. Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022; 20:1282.</a></li><li><a class="nounderline abstract_t">Ehrlich S, Mark AG, Rinawi F, et al. Micronutrient Deficiencies in Children With Inflammatory Bowel Diseases. Nutr Clin Pract 2020; 35:315.</a></li><li><a class="nounderline abstract_t">Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203.</a></li><li><a class="nounderline abstract_t">Grill BB, Lange R, Markowitz R, et al. Delayed gastric emptying in children with Crohn's disease. J Clin Gastroenterol 1985; 7:216.</a></li><li><a class="nounderline abstract_t">Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913.</a></li><li><a class="nounderline abstract_t">Gryboski JD, Burger J, McCallum R, Lange R. Gastric emptying in childhood inflammatory bowel disease: nutritional and pathologic correlates. Am J Gastroenterol 1992; 87:1148.</a></li><li><a class="nounderline abstract_t">Motil KJ, Grand RJ, Maletskos CJ, Young VR. The effect of disease, drug, and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure. J Pediatr 1982; 101:345.</a></li><li><a class="nounderline abstract_t">Motil KJ, Grand RJ, Matthews DE, et al. Whole body leucine metabolism in adolescents with Crohn's disease and growth failure during nutritional supplementation. Gastroenterology 1982; 82:1359.</a></li><li><a class="nounderline abstract_t">Szilagyi A, Galiatsatos P, Xue X. Systematic review and meta-analysis of lactose digestion, its impact on intolerance and nutritional effects of dairy food restriction in inflammatory bowel diseases. Nutr J 2016; 15:67.</a></li><li><a class="nounderline abstract_t">Nardone OM, Manfellotto F, D'Onofrio C, et al. Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Jasielska M, Grzybowska-Chlebowczyk U. Lactose Malabsorption and Lactose Intolerance in Children with Inflammatory Bowel Diseases. Gastroenterol Res Pract 2019; 2019:2507242.</a></li><li><a class="nounderline abstract_t">Jasielska M, Grzybowska-Chlebowczyk U. Hypocalcemia and Vitamin D Deficiency in Children with Inflammatory Bowel Diseases and Lactose Intolerance. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Perkal MF, Seashore JH. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:567.</a></li><li><a class="nounderline abstract_t">Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn's disease in children and adolescents. Pediatrics 1975; 55:866.</a></li><li><a class="nounderline abstract_t">Beeken WL. Absorptive defects in young people with regional enteritis. Pediatrics 1973; 52:69.</a></li><li><a class="nounderline abstract_t">Becker K, Berger M, Niederau C, Frieling T. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Hepatogastroenterology 1999; 46:2309.</a></li><li><a class="nounderline abstract_t">Becker K, Frieling T, Häussinger D. Quantification of fecal alpha 1-antitrypsin excretion for assessment of inflammatory bowel diseases. Eur J Med Res 1998; 3:65.</a></li><li><a class="nounderline abstract_t">Wiskin AE, Wootton SA, Cornelius VR, et al. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54:271.</a></li><li><a class="nounderline abstract_t">Wiskin AE, Haggarty R, Afzal NA, et al. Nutritional perspectives of children with Crohn's disease: a single-centre cohort observation of disease activity, energy expenditure and dietary intake. Eur J Clin Nutr 2016; 70:1132.</a></li><li><a class="nounderline abstract_t">Varille V, Cézard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1996; 23:13.</a></li><li><a class="nounderline abstract_t">Zoli G, Katelaris PH, Garrow J, et al. Increased energy expenditure in growing adolescents with Crohn's disease. Dig Dis Sci 1996; 41:1754.</a></li><li><a class="nounderline abstract_t">Malik S, Mason A, Bakhshi A, et al. Growth in children receiving contemporary disease specific therapy for Crohn's disease. Arch Dis Child 2012; 97:698.</a></li><li><a class="nounderline abstract_t">Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1483.</a></li><li><a class="nounderline abstract_t">Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 1999; 10:201.</a></li><li><a class="nounderline abstract_t">Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997; 37:50.</a></li><li><a class="nounderline abstract_t">Alemzadeh N, Rekers-Mombarg LT, Mearin ML, et al. Adult height in patients with early onset of Crohn's disease. Gut 2002; 51:26.</a></li><li><a class="nounderline abstract_t">Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19:1961.</a></li><li><a class="nounderline abstract_t">Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88:995.</a></li><li><a class="nounderline abstract_t">Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.</a></li><li><a class="nounderline abstract_t">Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr 2009; 101:676.</a></li><li><a class="nounderline abstract_t">Thangarajah D, Hyde MJ, Konteti VK, et al. Systematic review: Body composition in children with inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42:142.</a></li><li><a class="nounderline abstract_t">Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003; 98:1556.</a></li><li><a class="nounderline abstract_t">Steiner SJ, Noe JD, Denne SC. Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease. Pediatr Res 2011; 70:484.</a></li><li><a class="nounderline abstract_t">Barnes MJ, Lynch MK, Lisenby MD, et al. Conceptual Model of Lean Body Mass in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019; 68:301.</a></li><li><a class="nounderline abstract_t">Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105:1893.</a></li><li><a class="nounderline abstract_t">Ricciuto A, Mack DR, Huynh HQ, et al. Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease. J Crohns Colitis 2021; 15:419.</a></li><li><a class="nounderline abstract_t">Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18:165.</a></li><li><a class="nounderline abstract_t">Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.</a></li><li><a class="nounderline abstract_t">Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681.</a></li><li><a class="nounderline abstract_t">Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Andrews H, et al. Introduction to and Screening Visit Results of the Multicenter Pediatric Crohn's Disease Growth Study. Inflamm Bowel Dis 2020; 26:1945.</a></li><li><a class="nounderline abstract_t">Booth IW. The nutritional consequences of gastrointestinal disease in adolescence. Acta Paediatr Scand Suppl 1991; 373:91.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Determination of bone age in pediatric patients with Crohn's disease should become part of routine care. Inflamm Bowel Dis 2013; 19:61.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Kohn MA, et al. Sex differences in statural growth impairment in Crohn's disease: role of IGF-1. Inflamm Bowel Dis 2011; 17:2318.</a></li><li><a class="nounderline abstract_t">Herzog D, Fournier N, Buehr P, et al. Early-onset Crohn's disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol 2014; 26:1234.</a></li><li><a class="nounderline abstract_t">Connors J, Basseri S, Grant A, et al. Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis. J Crohns Colitis 2017; 11:1063.</a></li><li><a class="nounderline abstract_t">Cohen-Dolev N, Sladek M, Hussey S, et al. Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn's Disease: Results From the GROWTH CD Study. J Crohns Colitis 2018; 12:306.</a></li><li><a class="nounderline abstract_t">Bamberger S, Martinez Vinson C, Mohamed D, et al. Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies. PLoS One 2016; 11:e0163126.</a></li><li><a class="nounderline abstract_t">Sawczenko A, Ballinger AB, Croft NM, et al. Adult height in patients with early onset of Crohn's disease. Gut 2003; 52:454.</a></li><li><a class="nounderline abstract_t">Rinawi F, Assa A, Almagor T, et al. Prevalence and Predictors of Growth Impairment and Short Stature in Pediatric-Onset Inflammatory Bowel Disease. Digestion 2020; 101:674.</a></li><li><a class="nounderline abstract_t">Gupta N, Liu C, King E, et al. Continued Statural Growth in Older Adolescents and Young Adults With Crohn's Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure. Inflamm Bowel Dis 2020; 26:1880.</a></li><li><a class="nounderline abstract_t">Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ 1994; 308:1259.</a></li><li><a class="nounderline abstract_t">Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:83.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric patients with Crohn's disease. Dig Dis Sci 2012; 57:2975.</a></li><li><a class="nounderline abstract_t">Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:11.</a></li><li><a class="nounderline abstract_t">Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.</a></li><li><a class="nounderline abstract_t">Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:42.</a></li><li><a class="nounderline abstract_t">Ronel N, Tzion RL, Orlanski-Meyer E, et al. Clinical Criteria Can Identify Children With Osteopenia in Newly Diagnosed Crohn Disease. J Pediatr Gastroenterol Nutr 2021; 72:270.</a></li><li><a class="nounderline abstract_t">Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228.</a></li><li><a class="nounderline abstract_t">Laakso S, Valta H, Verkasalo M, et al. Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study. J Pediatr 2014; 164:1436.</a></li><li><a class="nounderline abstract_t">Abraham BP, Prasad P, Malaty HM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci 2014; 59:1878.</a></li><li><a class="nounderline abstract_t">American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.</a></li><li><a class="nounderline abstract_t">Hill RJ, Brookes DS, Davies PS. Bones in pediatric Crohn's disease: a review of fracture risk in children and adults. Inflamm Bowel Dis 2011; 17:1223.</a></li><li><a class="nounderline abstract_t">Markel TA, Lou DC, Pfefferkorn M, et al. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis. Surgery 2008; 144:540.</a></li><li><a class="nounderline abstract_t">Alves A, Panis Y, Bouhnik Y, et al. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007; 50:331.</a></li><li><a class="nounderline abstract_t">Thavamani A, Umapathi KK, Khatana J, Gulati R. Burden of Psychiatric Disorders among Pediatric and Young Adults with Inflammatory Bowel Disease: A Population-Based Analysis. Pediatr Gastroenterol Hepatol Nutr 2019; 22:527.</a></li><li><a class="nounderline abstract_t">Cushman G, Stolz MG, Shih S, et al. Age, Disease Symptoms, and Depression are Associated With Body Image Dissatisfaction in Newly Diagnosed Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021; 72:e57.</a></li><li><a class="nounderline abstract_t">Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.</a></li><li><a class="nounderline abstract_t">Miele E, Shamir R, Aloi M, et al. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66:687.</a></li><li><a class="nounderline abstract_t">Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996; 12:151.</a></li><li><a class="nounderline abstract_t">Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356.</a></li><li><a class="nounderline abstract_t">Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Isr Med Assoc J 2008; 10:503.</a></li><li><a class="nounderline abstract_t">Harrison ME, Norris ML, Robinson A, et al. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review. Appetite 2019; 137:62.</a></li><li><a class="nounderline abstract_t">Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011; 27:651.</a></li><li><a class="nounderline abstract_t">Maxwell EC, Dawany N, Baldassano RN, et al. Diverting Ileostomy for the Treatment of Severe, Refractory, Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017; 65:299.</a></li><li><a class="nounderline abstract_t">Pacilli M, Eaton S, Fell JM, et al. Surgery in children with Crohn disease refractory to medical therapy. J Pediatr Gastroenterol Nutr 2011; 52:286.</a></li><li><a class="nounderline abstract_t">Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.</a></li><li><a class="nounderline abstract_t">Gupta N, Lustig RH, Chao C, et al. Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn's disease. World J Gastroenterol 2018; 24:2036.</a></li><li><a class="nounderline abstract_t">Han PD, Burke A, Baldassano RN, et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:423.</a></li><li><a class="nounderline abstract_t">Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989; 97:905.</a></li><li><a class="nounderline abstract_t">Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.</a></li><li><a class="nounderline abstract_t">Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543.</a></li><li><a class="nounderline abstract_t">Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 2005; 11:435.</a></li><li><a class="nounderline abstract_t">Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr 2008; 153:651.</a></li><li><a class="nounderline abstract_t">Wong SC, Hassan K, McGrogan P, et al. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab 2007; 20:1315.</a></li><li><a class="nounderline abstract_t">Wong SC, Kumar P, Galloway PJ, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin Endocrinol (Oxf) 2011; 74:599.</a></li><li><a class="nounderline abstract_t">Denson LA, Kim MO, Bezold R, et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010; 51:130.</a></li><li><a class="nounderline abstract_t">Vortia E, Kay M, Wyllie R. The role of growth hormone and insulin-like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr Opin Pediatr 2011; 23:545.</a></li><li><a class="nounderline abstract_t">Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr 2011; 75:8.</a></li></ol></div><div id="topicVersionRevision">Topic 5893 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266237" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for the management of growth failure in childhood inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21560194" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Variables Associated With Statural Growth in Pediatric Crohn's Disease Differ by Sex (The Growth Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877976" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925610" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Growth Pattern in Paediatric Crohn Disease Is Related to Inflammatory Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034910" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interventions for growth failure in childhood Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748390" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324398" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206672" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150651" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Improvement in growth of children with Crohn disease following anti-TNF-αtherapy can be independent of pubertal progress and glucocorticoid reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162032" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increased effectiveness of early therapy with anti-tumor necrosis factor-αvs an immunomodulator in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27657882" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301428" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26074699" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226647" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease: Associations With Adalimumab Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913894" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease--a multicenter European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037779" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764714" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150725" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016005" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interleukin-6 stimulates lipolysis in porcine adipocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21337672" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30881894" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846217" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469794" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984988" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893990" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Body height in paediatric inflammatory bowel diseases: A structural equation model analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350215" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dietary intake and nutritional treatment in childhood Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402936" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dietary intakes of children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426315" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gastric emptying and disease activity in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216812" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10702205" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The role of medial hypothalamic serotonin in the suppression of feeding in a rat model of colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11814426" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34106253" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessing the Prevalence of and Risk Factors for Disordered Eating Attitudes and Behaviors in Adolescents With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34389486" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31342601" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Micronutrient Deficiencies in Children With Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9301499" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4020081" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Delayed gastric emptying in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1885073" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Gastric emptying in childhood inflammatory bowel disease: nutritional and pathologic correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6809923" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of disease, drug, and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6802699" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Whole body leucine metabolism in adolescents with Crohn's disease and growth failure during nutritional supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411934" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Systematic review and meta-analysis of lactose digestion, its impact on intolerance and nutritional effects of dairy food restriction in inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33919766" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31871445" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lactose Malabsorption and Lactose Intolerance in Children with Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34444743" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypocalcemia and Vitamin D Deficiency in Children with Inflammatory Bowel Diseases and Lactose Intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2509355" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nutrition and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1079596" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical manifestations of Crohn's disease in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4724441" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Absorptive defects in young people with regional enteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10521988" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9512970" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quantification of fecal alpha 1-antitrypsin excretion for assessment of inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21921807" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : No relation between disease activity measured by multiple methods and REE in childhood Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27329610" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nutritional perspectives of children with Crohn's disease: a single-centre cohort observation of disease activity, energy expenditure and dietary intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8811517" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794790" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Increased energy expenditure in growing adolescents with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22685044" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Growth in children receiving contemporary disease specific therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641119" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Delayed puberty and response to testosterone in a rat model of colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484284" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of cytokines in testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9138453" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Review: cytokine involvement in ovarian processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077087" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adult height in patients with early onset of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537438" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612366" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Presenting features of inflammatory bowel disease in Great Britain and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961699" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18631418" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26043941" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Systematic review: Body composition in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873577" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Body composition in patients with inflammatory bowel disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814156" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30499883" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Conceptual Model of Lean Body Mass in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145606" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Nutritional status and growth in pediatric Crohn's disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978629" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014763" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Longitudinal growth in children and adolescents with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187775" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8359640" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Growth failure in children with inflammatory bowel disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3181677" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32190893" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Introduction to and Screening Visit Results of the Multicenter Pediatric Crohn's Disease Growth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1927534" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The nutritional consequences of gastrointestinal disease in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22552908" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Determination of bone age in pediatric patients with Crohn's disease should become part of routine care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21287667" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sex differences in statural growth impairment in Crohn's disease: role of IGF-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25089544" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early-onset Crohn's disease is a risk factor for smaller final height.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575325" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29165666" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn's Disease: Results From the GROWTH CD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27636201" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis FactorαAntibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584236" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Adult height in patients with early onset of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522182" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prevalence and Predictors of Growth Impairment and Short Stature in Pediatric-Onset Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31968095" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Continued Statural Growth in Older Adolescents and Young Adults With Crohn's Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205017" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Juvenile onset inflammatory bowel disease: height and body mass index in adult life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8003745" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Growth and puberty in chronic inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22744430" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Menarche in pediatric patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694532" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Skeletal health of children and adolescents with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516861" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206638" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810035" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical Criteria Can Identify Children With Osteopenia in Newly Diagnosed Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071937" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reduced bone density in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24650398" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619280" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612916" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824813" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Bones in pediatric Crohn's disease: a review of fracture risk in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847637" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17252288" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777718" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Burden of Psychiatric Disorders among Pediatric and Young Adults with Inflammatory Bowel Disease: A Population-Based Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32925551" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Age, Disease Symptoms, and Depression are Associated With Body Image Dissatisfaction in Newly Diagnosed Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3875704" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinical longitudinal standards for height and height velocity for North American children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29570147" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8798217" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Nutritional considerations and management of the child with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162683" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18751627" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30825493" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21241207" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28045769" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Diverting Ileostomy for the Treatment of Severe, Refractory, Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975579" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Surgery in children with Crohn disease refractory to medical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040176" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29760546" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372275" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nutrition and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2506101" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3123302" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Chronic intermittent elemental diet improves growth failure in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707085" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Supplementary enteral nutrition maintains remission in paediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867582" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589450" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Growth hormone treatment for growth failure in pediatric patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18341091" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470283" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453679" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A randomized controlled trial of growth hormone in active pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900782" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The role of growth hormone and insulin-like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664179" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
